Shares of Oncolytics Biotech Inc (TSX: ONC), engaged in the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers, recorded over a 13.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. ONC was the top performer in the Canada healthcare sector after gaining 13.7% and closed at C$0.91 Thursday, while recording significant trading volumes of 336,367 shares. During the past 5-trading sessions, ONC gained 65.5% with daily average trading volumes of 203,723 shares, while the stock accumulated 42.2% gain during the past one month with daily average trading volumes of 162,528 shares.
Company Description:
Oncolytics Biotech Inc. (TSX: ONC) discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.
1-Year Stock Chart:
Source: Bloomberg
